Join

Compare · PKI vs SEER

PKI vs SEER

Side-by-side comparison of PerkinElmer Inc. (PKI) and Seer Inc. (SEER): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both PKI and SEER operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
  • PKI is the larger of the two at $21.38B, about 217.3x SEER ($98.4M).
  • SEER has hit the wire 17 times in the past 4 weeks while PKI has been quiet.
  • PKI has more recent analyst coverage (17 ratings vs 8 for SEER).
MetricPKISEER
Company
PerkinElmer Inc.
Seer Inc.
Price
$115.23-0.88%
$1.80+0.84%
Market cap
$21.38B
$98.4M
1M return
-
-4.51%
1Y return
-
-18.37%
Industry
Biotechnology: Laboratory Analytical Instruments
Biotechnology: Laboratory Analytical Instruments
Exchange
NYSE
NASDAQ
IPO
2020
News (4w)
0
17
Recent ratings
17
8
PKI

PerkinElmer Inc.

PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as laboratory services. It also provides analytical technologies, solutions, and services for the environmental, food, and industrial markets that enable its customers to understand the characterization and health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology and drug discovery. The company serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.

SEER

Seer Inc.

Seer, Inc., a life sciences company, engages in developing and commercializing products for researchers to unlock biological information. The company develops Proteograph Product Suite, an integrated solution that comprises consumables, an automation instrumentation, and software that provides workflow to make proteomic profiling, and the analysis of the samples needed to characterize the nature of the proteome. It intends to sell its products for research purposes, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. Seer, Inc. has a collaboration agreement with Discovery Life Sciences, LLC. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.

Latest PKI

Latest SEER